Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

NCT04101331 is registered in ClinicalTrials.gov with Affimed GmbH as lead sponsor.

NCT NCT04101331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04101331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)
Lead sponsor
Affimed GmbH
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2019
Completion date
January 11, 2024
Enrollment
108 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma, transformed mycosis fungoides